Tips for searching:
• You have to select a product and type at least 2 words to activate the search
• Use only words that are specific to the information you are looking for
• Avoid typing questions or sentences
Please do not use this field to report adverse events or product complaints. Adverse events and product complaints should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow card in the Google play or Apple app store. Adverse events and product complaints should also be reported to Lilly: please call Lilly UK on 01256 315 000.
Mounjaro ® ▼ (tirzepatide)
This information is intended for UK registered healthcare professionals only in response to your search for information. For current information for all Lilly products, including Summaries of Product Characteristics, Patient Information Leaflets and Instructions for Use, please visit: www.medicines.org.uk
What do the lines on the Mounjaro® KwikPen® cartridge mean?
The lines on the Mounjaro KwikPen are not intended to indicate the number of doses remaining. They are part of the overall design of the pen but do not serve a specific function.
Please note: A modified version of the Mounjaro KwikPen will be available on the market at the same time as the initial version. While the two versions may look slightly different, they work in the same way.1 The information provided in this document applies to both the modified and initial KwikPens.
The marks on the pen can not be used as dose indicators.1
References
1Data on file, Eli Lilly and Company and/or one of its subsidiaries.
▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.
Date of Last Review: 14 August 2025